SB 140

The bill states that the Colorado prescription drug affordability review board has no authority to perform an affordability review of, or to establish an upper payment limit for, a prescription drug that is: Designated as a drug for a rare disease or condition by the food and drug administration (FDA) of the federal department of health and human services; or A licensed biological product that is derived from human whole blood or plasma as indicated on product labeling approved by the FDA. (Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)